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Objectives. This study examined the elects of early long-term 
monotherapy with enalapril on the severity of functional mitral 
regurgitation in dogs with moderate heart failure. 
Background. Functional mitrai regurgitation often develops in 
patients with heart failure and, depending on its severity, can have 
a marked adverse impact on the stroke output of the failing left 
ventricle and contribute to progressive deterioration of the heart 
failure state. 
Methods. Left ventricular dysfunction (ejection fraction 30% to 
40%) was produced in 14 dogs by multiple sequential intracoro- 
nary microembolizations. Dogs were randomized to 3 months of 
therapy with enalapril (10 mg twice daily, n = 7) or no therapy at 
all (control, n = 7). The severity of functional mitral regurgitation 
was quantified by Doppler color flow mapping in seven control 
and six enalapril-treated dogs. Mitral annular diameter was 
assessed by echocardiography and left ventricular volumes and 
shape by ventriculography. Measurements were made before 
initiation and after completion of therapy. 
Results. In control dogs, the severity of mitral regurgitation 
increased uring the follow-up period ([mean -+ SEM] 14 -+ 4 vs. 
23 -+ 4%, p < 0.001) and was associated with increased left 
ventricular end-systolic and end-diastolic volumes. In contrast, 
the severity of regurgitation was not significantly changed in dogs 
treated with enalapril (18 -+ 3 vs. 16 -+ 6%, p < 0.59) and was 
associated with preservation of left ventricular volumes. 
Conclusions. In dogs with moderate heart failure, early long- 
term therapy with enalapril prevents progressive worsening of 
functional mitral regurgitation. This beneficial effect is most likely 
achieved by prevention of progressive left ventricular dilation. 
(J Am Coil Cardiol 1995;25:768-72) 
The heart failure state is characterized by a progressive 
inability of the left ventricle to provide sutficient stroke output 
to maintain proper perfusion to vital organs. As a consequence 
of this failure, compensatory vasoconstrictor systems are elic- 
ited in an attempt to maintain organ perfusion pressure (1,2). 
In many patients with heart failure this condition is further 
complicated by the development of functional mitral regurgi- 
tation (3,4). Once established, and depending on its severity, 
functional mitral regurgitation can further educe the effective 
stroke output of the failing left ventricle, leading to further 
activation of vasoconstrictor systems to maintain homeostasis. 
From this perspective, functional mitral regurgitation can be 
viewed as an important component of the progressive deteri- 
oration of ventricular pump function that characterizes the 
heart failure state. Accordingly, any therapeutic nterventions 
that can potentially lead to prevention of functional mitral 
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regurgitation or to a reduction in the severity of the existing 
regurgitation can be considered beneficial in the treatment of 
this disease state. Acute afterload reduction with intravenous 
vasodilators in patients with heart failure has been shown to 
decrease the severity of functional mitral regurgitation and 
result in an improvement of left ventricular forward stroke 
volume (5,6). However, there is little information with regard 
to the effects of long-term therapy with drugs such as angio- 
tensin-converting enzyme inhibitors on the severity of func- 
tional mitral regurgitation. 
The progression toward overt heart failure is often accom- 
panied by marked topographic remodeling of the left ventricle 
(7,8). Global components of this remodeling process include 
ventricular enlargement, increased chamber sphericity and 
dilation of the mitral valve annulus. All of these features of 
ventricular emodeling have been implicated in the etiology 
and severity of functional mitral regurgitation (4,9,10). Studies 
in patients and in dogs with heart failure (11-13) have shown 
that therapy with angiotensin-converting e zyme inhibitors can 
have a favorable effect on ventricular emodeling. In the 
present study, we tested the hypothesis that in dogs with 
moderate heart failure, early therapy with enalapril will pre- 
vent worsening of existing functional mitral regurgitation by 
preventing or attenuating the process of progressive l ft ven- 
tricular chamber remodeling. 
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Methods  
Animal model. The canine model of chronic heart failure 
used in this study has been described in detail (14). In this 
model, chronic left ventricular dysfunction is produced by 
multiple sequential intracoronary embolizations with polysty- 
rene latex microspheres (77 to 102/xm in diameter) (14). A 
unique feature of this model is the continued progressive 
deterioration in left ventricular function long after cessation of 
coronary embolizations (14,15). In the present study, 14 dogs 
weighing between 18 and 31 kg underwent multiple intracoro- 
nary microembolizations -1 to 3 weeks apart. Embolizations 
were performed uring cardiac atheterizations under general 
anesthesia and sterile conditions. Anesthesia consisted of a 
combination of intravenous oxymorphone (0.22 mg/kg body 
weight), diazepam (0.17 mg/kg) and sodium pentobarbital (150 
to 250 mg to effect). This anesthesia regimen was previously 
shown to have no effect on global eft ventricular function (11). 
Embolizations were discontinued when left ventricular ejection 
fraction, determined angiographically, was between 30% and 
40%. The cohort of dogs used in the present study represents 
a subset of the larger study (11). 
Study protocol. Three weeks after the last embolization, 
dogs underwent a left and right heart catheterization to
establish emodynamic status. One day later, dogs were ran- 
domized to 3 months of oral monotherapy with enalapril 
(10 mg twice daily, n = 7) or no therapy at all (control dogs, 
n = 7). One dog treated with enalapril was excluded from the 
study because a color flow Doppler study was not obtained 
before randomization. Accordingly, the results presented in 
this study are based on seven control dogs and six enalapril- 
treated ogs. Hemodynamic, angiographic, echocardiographic 
and color flow Doppler measurements were made during 
cardiac catheterization 1 day before initiation of therapy and 
were repeated uring a cardiac catheterization performed at 
the end of 3 months of therapy. The anesthesia regimen 
described earlier was used for both cardiac catheterizations. 
The study was approved by the Henry Ford Hospital Care of 
Experimental Animals Committee and conformed to the "Po- 
sition of the American Heart Association on Research Animal 
Use" adopted by the Association in November 1984, and to the 
guiding principles of the American Physiological Society. 
Hemodynamic and ventrieulographie measurements. 
Aortic and left ventricular pressures were measured with 
catheter-tipped micromanometers (Millar Instruments). Mean 
pulmonary artery wedge pressure was measured using a Swan- 
Ganz catheter in conjunction with a P23XL pressure trans- 
ducer (Spectramed). The mean systolic transmitral pressure 
gradient was calculated as the difference between mean left 
ventricular systolic and mean pulmonary artery wedge pres- 
sures. Mean left ventricular systolic pressure was calculated by 
integration of the area under the systolic portion of the 
pressure waveform. The onset of systole was assumed to 
coincide with the level of end-diastolic pressure (closure of 
mitral valve) and the end of ventricular systole to coincide with 
the level of pressure qual to end-diastolic pressure on the 
downstroke ofthe left ventricular pressure waveform (opening 
of mitral valve). Cardiac output was measured in duplicate 
using the thermodilution method. Stroke volume was calcu- 
lated as the ratio of cardiac output o heart rate. Stroke index 
was calculated as the ratio of stroke volume to body surface 
area. Systemic vascular esistance was calculated as previously 
described (14). 
Left ventriculograms were obtained after completion of the 
hemodynamic measurements with the dog placed on its right 
side and were recorded on 35-mm cine film at 30 frames/s 
during the injection of 20 ml of contrast material (Hypaque 
meglumine 60%, Winthrop Pharmaceutical). Correction for 
image magnification was made with a radiopaque calibrated 
grid placed at the level of the left ventricle. Left ventricular 
end-systolic and end-diastolic volumes were calculated from 
ventricular silhouettes using the area-length method (16) and 
were corrected for body surface area. Ejection fraction was 
calculated as previously described (14). Global indexes of left 
ventricular shape were used to quantitate changes in chamber 
sphericity. Left ventricular shape was quantified from angio- 
graphic silhouettes on the basis of the major/minor axis ratio at 
end-systole and end-diastole (17,18). As this ratio decreases 
(approaches unity), the shape of the ventricle approaches that 
of a sphere. Extrasystolic and post-extrasystolic beats were 
excluded from all ventriculograpbic analyses. 
Echoeardiographic measurements. Echocardiographic 
studies were performed using a 77020A ultrasound system 
(Hewlett-Packard) with a 2.5-MHz transducer. All echocardio- 
graphic measurements were made with the dog placed in the 
right lateral decubitus position. Echocardiograms were re- 
corded on a Panasonic 6300 VHS recorder for off-line analysis. 
Mitral annular diameter was calculated by averaging three 
individual measurements obtained from three separate cho- 
cardiographic projections, namely, aparasternal long-axis view 
and apical two- and four-chamber views (18). The mitral 
annulus diameter was measured uring diastole just before 
atrial contraction and during midsystole. These two measure- 
ments were chosen because the mitral annulus diameter is 
maximal and minimal at these respective times during the 
cardiac cycle (19). The apical four-chamber view was used to 
calculate the perpendicular distance D between the point of 
coaptation ofthe mitral eaflets and the mitral annulus plane at 
end-systole, as previously described (20). 
Quantitation of severity of mitral regurgitation. The pres- 
ence of functional mitral regurgitation was determined with 
Doppler color flow mapping (Hewlett-Packard model 77020A 
ultrasound system) using both apical two- and four-chamber 
views. In both views, the severity of mitral regurgitation was 
determined on the basis of the ratio of the regurgitant jet area 
to the area of the left atrium times 100 (20,21). The ratios 
calculated from both views were then averaged to obtain a 
single representative measure of the severity of regurgitation. 
Doppler studies were obtained in all dogs randomized to no 
treatment and in six of the seven dogs randomized totreatment 
with enalapril. Assessment of the severity of mitral regurgita- 
tion was performed by two readers in blinded manner. The 
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Table 1. Hemodynamic, Angiographic, Echocardiographic and Doppler Measurements Before and After Therapy 
Control Dogs (n = 7) Enalapril-Treated Dogs (n - 6) 
Before After p Value* Before After p Value* 
EF (%) 36 _+ 1 26 -- 1 < 0.001 34 _+ 2 39 + 4 < 0.18 
EDVI (ml/m 2) 71 _+ 7 86 _+ 9 < 0.007 67 -+ 8 72 _+ 7 < 0.24 
ESVI (ml/m 2) 44 _+ 5 64 ÷ 7 < 0.002 44 _+ 5 44 _+ 5 < 0.094 
MR (%) 14 +_ 4 23 ÷ 4 < 0.001 18 _+ 3 16 _+ 6 < 0.59 
SI (ml/m 2) 42 _+ 4 33 +_ 6 < 0.002 39 _+ 4 43 _+ 4 < 0.07 
SVR (dynes. s. cm s) 2,620 + 250 3,000 +_ 147 < 0.05 2,347 _+ 172 2,152 _+ 225 < 0.44 
Ap (mm Hg) 68 +- 5 75 _+ 5 < 0.37 67 _+ 6 66 _+ 7 < 0.82 
ESR 1.56 _+ 0.04 1.42 _+ 0.04 < 0.030 1.51 _+ 0.08 1.46 _+ 0.10 < 0.67 
EDR 1.43 _+ 0.04 1.29 _+ 0.05 < 0.020 1.36 + 0.07 1.27 _+ 0.08 < 0.36 
D (em) 0.94 + 0.03 1.11 _+ 0.07 < 0.007 0.87 + 0.03 0.82 + 0.05 < 0.36 
MADs (cm) 3.2 _+ 0.1 3.4 _+ 0.1 < 0.022 3.3 _+ 0.1 3.3 + 0.1 < 0.61 
MADd (cm) 3.4 +_ 0.1 3.6 _+ 0.2 < 0.008 3.4 _+ 0.1 3.5 -+ 0.1 < 0.29 
*Before versus after therapy comparisons. Data presented are mean values +_ SEM. D - distance D; EDR (ESR) = left ventficular end-diastolic (end-systolic) sphericity 
ratio; EDVI (ESVI) = left ventricular end-diastolic (end-systolic) volume index; EF = left ventricular ejection fraction; MADd (MADs) = diastolic (systolic) mitra! annular 
diameter; MR = severity of mitral regurgitation; SI - stroke index; SVR - systemic vascular resistance; Ap = transmitral pressure gradient during systole. 
average of these two readings are reported. Functional mitral 
regurgitation was not present before initiation of therapy in 
one dog randomized to the no-treatment group. In this dog a 
value of 0% was used in the calculations. This value was used 
because this dog developed mitral regurgitation atthe end of 
the 3-month follow-up period. 
Data analysis. Comparisons of hemodynamic, anglo- 
graphic, echocardiographic and Doppler measures were made 
between values obtained before and those obtained at the end 
of therapy within each of the study groups. For these compar- 
isons, a Student paired t test was used, and p -< 0.05 was 
considered significant. To ensure that all study outcome mea- 
sures were similar before initiation of therapy, comparisons 
were made between the untreated group (control) and the 
enalapril-treated groups. For these comparisons, a t-statistic 
for two means was used, and p -< 0.05 was considered 
significant. Significance of treatment effect was examined by 
comparing the two study groups on the basis of the change in 
each hemodynamic, angiographic and Doppler echocardio- 
graphic measure between pretreatment and posttreatment. 
For these comparisons, a t statistic for two means was used, 
and p -< 0.05 was considered significant. All data are reported 
as the mean value _+ SEM. 
Resu l ts  
None of the dogs used in the study had mitral regurgitation 
at baseline (before any embolizations). Six of seven dogs 
randomized to the control group had functional mitral regur- 
gitation at the time of randomization. All seven dogs random- 
ized to the control group had mitral regurgitation at the end of 
3 months of follow-up. All six dogs randomized to receive 
enalapril had mitral regurgitation atthe beginning of therapy, 
but only five showed regurgitation at the end of therapy. There 
were no significant differences in any of the hemodynamic, 
angiographic, echocardiographic or Doppler variables before 
initiation of therapy between control dogs and dogs treated 
with enalapril (Table 1). The total volume of intracoronary 
microspheres used to produce chronic left ventricular dysfunc- 
tion was not significantly different in untreated (11 + 1 ml) 
versus enalapril-treated dogs (10 _+ 2 ml). 
Severity of mitral regurgitation in untreated control dogs. 
As anticipated, on the basis of previous observations (14,15), in 
dogs randomized to no treatment, left ventricular ejection 
fraction decreased significantly during the 3-month follow-up 
period and was associated with a significant increase in left 
ventricular end-systolic and end-diastolic volume indexes and 
systemic vascular resistance (Table 1). In this group, functional 
mitral regurgitation worsened uring the 3 months of follow- 
up. Severity of regurgitation was 14 _+ 4% at the beginning of 
follow-up and increased to 23 _+ 4% at the end of follow-up 
(p < 0.001). This increase in severity of mitral regurgitation 
was associated with a significant decrease in stroke index 
(Table 1). There was no statistically significant increase in the 
mean systolic transmitral pressure gradient measured before 
follow-up compared with that measured at the end of fol- 
low-up (Table 1). In contrast, here was a significant decrease 
in left ventricular end-systolic and end-diastolic major/minor 
axis ratios and a significant increase in the distance D and in 
mitral annular diameter measured uring systole and diastole 
(Table 1). 
Severity of mitral regurgitation in dogs treated with enala- 
prii. Enalapril therapy prevented the progressive decline in 
left ventricular ejection fraction, preserved the end-systolic 
volume index and markedly attenuated the increase in end- 
diastolic volume index (Table 1). Systemic vascular esistance 
was essentially unchanged (Table 1). In this group, there was 
no significant worsening of functional mitral regurgitation. 
Severity of regurgitation was 18 _+ 3% before and 16 _+ 6% 
after of 3 months of therapy. There were no significant changes 
in stroke index, mean systolic transmitral pressure gradient, 
indexes of left ventricular shape, distance D or mitral annular 
diameters measured uring systole and diastole (Table 1). 
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Table 2. Change in Hemodynamic, Angiographic, 
Echocardiographic and Doppler Measurements in Treated and 
Untreated Dogs 
Enalapril-Treated 
Control Dogs Dogs 
(n - 7) (n = 6) p Value* 
EF (%) -9  _+ 1 5 - 3 < 0,001 
EDVI (ml/m 2) 16 _+ 4 5 + 4 < 0.060 
ESVI (ml/m 2) 20 _+ 4 1 + 3 < 0.003 
SVI (ml/m 2) -9  + 2 4 + 2 < 0.001 
SVR (dynes" s '  cm s) 377 _+ 153 -395 ~+ 176 < 0.016 
AP (ram Hg) 7 _+ 7 -1 + 5 < 0.390 
ESR -0.13 _+ 0.05 -0.05 + 0.1 < 0.440 
EDR -0.14 _+ 0.04 -0.09 + 0.09 < 0.620 
D (cm) 0.2 _+ 0.04 -0.1 ___ 0.05 < 0.006 
MADs (cm) 0.1 + 0.04 0.03 _+ 0.06 < 0.220 
MADd (cm) 0.3 +_ 0.1 0.1 _+ 0.1 < 0.17 
*Control versus enalapril-treated dogs. Data presented are mean value _+ 
SEM. Abbreviations as in Table 1. 
Comparison of treatment effect (control vs. enalapril). A 
significant difference was observed between untreated and 
enalapril-treated dogs with respect to change in ejection 
fraction, stroke index and systemic vascular esistance (Table 
2). Change in severity of functional mitral regurgitation was 
significantly higher in untreated (9 ___ 1%) than in enalapril- 
treated (-3 _+ 5%, p < 0.025) dogs. This improvement was 
associated with significant differences between the two groups 
with respect o left ventricular end-systolic volume index and 
distance D and borderline significance with respect o left 
ventricular end-diastolic volume index (Table 2). However, 
there were no significant differences between the two groups 
with respect to measures of left ventricular chamber sphericity, 
mean systolic transmitral pressure gradient and systolic and 
diastolic mitral annular diameters (Table 2). 
Discuss ion  
The results of the present study indicate that early therapy 
with enalapril can prevent an increase in the severity of 
preexisting functional mitral regurgitation i  dogs with pro- 
gressive left ventricular dysfunction. This apparent beneficial 
effect was accompanied by a preservation of forward stroke 
output and by attenuation of left ventricular chamber enlarge- 
ment. In contrast o dogs treated with active drug, dogs that 
were randomized to no therapy manifested significant worsen- 
ing of functional mitral regurgitation. The increased severity of 
mitral regurgitation i  untreated ogs was associated with a 
decline in left ventricular stroke index and progressive left 
ventricular chamber dilation. 
Factors affecting left ventricular stroke output. There is no 
doubt hat increased severity of functional mitral regurgitation 
can in itself contribute to a reduction in the effective stroke 
output of the failing left ventricle. However, the observation i
the present study of increasing severity of mitral regurgitation 
in untreated ogs cannot be considered as the only feature 
responsible for the progressive decline in ventricular stroke 
output. Other factors may also contribute to this decline, 
including progressive worsening of ventricular systolic function 
as evidenced by a decrease in ejection fraction and a progres- 
sive increase in systemic vascular resistance. Similarly, the 
maintenance of ejection fraction and systemic vascular esis- 
tance in the enalapril-treated group must also be considered 
important additional factors that help maintain ventricular 
stroke output. 
Factors affecting severity of regurgitation. Although the 
etiology of functional mitral regurgitation appears to be dic- 
tated primarily by changes in global left ventricular shape 
(increased chamber sphericity) (3,10,17,18), the severity of the 
ensuing regurgitation is likely to be dictated by hemodynamic 
as well as global structural changes in left ventricular topogra- 
phy. From a hemodynamic standpoint, he pressure difference 
across the mitral valve during systole is a primary determinant 
of severity of mitral regurgitation. An increase in this pressure 
gradient can elicit an increase in severity of regurgitation, 
whereas a reduction in this pressure gradient can reduce 
severity of mitral regurgitation. It has long been recognized 
that acute afterload and preload reduction with intravenous 
vasodilators in patients with heart failure can reduce the 
severity of functional mitral regurgitation and, consequently, 
improve left ventricular stroke volume (5,6). However, in the 
present study, this hemodynamic determinant of severity of 
mitral regurgitation was not significantly altered in untreated 
or enalapril-treated dogs. It appears, therefore, that alteration 
in the magnitude of the systolic transmitral pressure gradient 
was not a main contributor to either the observed augmenta- 
tion or the reduction in severity of functional mitral regurgi- 
tation. 
Specific alteration in global eft ventricular topography can 
also contribute to alterations in severity of functional mitral 
regurgitation once established. These global components of 
the ventricular emodeling process include progressive left 
ventricular enlargement (9), increased left ventricular chamber 
sphericity (3,10,17,18) and mitral annular dilation (4). Left 
ventricular dilation is thought to induce retraction of the mitral 
valve leaflets by the chordae tendineae and papillary muscle, 
leading to incomplete coaptation of the mitral leaflets during 
systole (9). A progressive increase in left ventricular chamber 
sphericity can produce a further increase in misalignment of 
the papillary muscles with the mitral annulus, which also leads 
to incomplete coaptation of the mitral leaflets during systole 
(3,10,17,18). Finally, if the mitral annular ring dilates suffi- 
ciently, the valvular cusps may fail to meet fully, resulting in 
incomplete leaflet coaptation (4). In the present study, all 
three of these left ventricular remodeling features worsened in 
untreated ogs and were associated with increased severity of 
mitral regurgitation and a further increase in the perpendicular 
distance D between the coaptation point of the mitral leaflets 
and the mitral annular plane, suggesting poorer approximation 
of the mitral leaflets at the end of systole (20). In dogs treated 
with enalapril, progressive deterioration in all of the three 
remodeling features was prevented, as was the increase in the 
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perpendicular distance D. However, comparison of the two 
groups indicates that enalapril prevented the worsening of 
functional mitral regurgitation primarily by preventing or 
attenuating the extent of progressive l ft ventricular chamber 
enlargement. Although the present study suggests an associa- 
tion between the severity of functional mitral regurgitation and 
alterations in left ventricular emodeling variables, a clear 
cause-and-effect relation could not be established for any 
single remodeling variable. 
Significance. The present observations do not negate the 
commonly used therapeutic approach of load reduction as a 
means of treating patients with established heart failure. 
Vasodilator therapy has clearly been shown to ameliorate 
functional mitral regurgitation and improve left ventricular 
stroke output in these patients (5,6). The results of this study 
also do not imply that intravenous therapy with vasodilators in
such patients hould be replaced by therapy with angiotensin- 
converting enzyme inhibitors. Instead, these observations sug- 
gest that the functional mitral regurgitation that develops 
during the course of progressive deterioration of left ventric- 
ular function, which ultimately may lead to overt heart failure, 
can be attenuated by early treatment with angiotensin- 
converting enzyme inhibitors. This long-term benefit appears 
to be derived from the ability of these drugs to attenuate the 
process of progressive l ft ventricular enlargement. In a recent 
study of patients with normal ejection fractions and moderate 
to severe mitral regurgitation of varying etiologies (22), 1-year 
therapy with quinapril was shown to reduce severity of regur- 
gitation associated with a reduction in left ventricular end- 
diastolic and end-systolic volumes. Long-term therapy with the 
beta-adrenergic blocking agent metoprolol in patients with 
idiopathic dilated cardiomyopathy as also been shown (23) to 
attenuate the severity of functional mitral regurgitation asso- 
ciated with a reduction in left ventricular chamber dimensions. 
Conclusions. The results of the present study indicate that 
early long-term therapy with enalapril can attenuate the pro- 
gressive worsening of functional mitral regurgitation i  dogs 
with moderate heart failure. The changes in severity of mitral 
regurgitation do not appear to result from changes in the mean 
systolic transmitral pressure gradient. Instead, the beneficial 
long-term effects of enalapril on the severity of functional 
mitral regurgitation appear to result primarily from prevention 
or attenuation of progressive l ft ventricular chamber remod- 
eling, or both. 
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